Cargando…
Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
BACKGROUND: Dead-time correction is required for accurate quantitative SPECT-based dosimetry in the context of personalised (177)Lu radiopharmaceutical therapy. We aimed to evaluate the impact of applying dead-time correction on the reconstructed SPECT image versus on the acquisition projections bef...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385894/ https://www.ncbi.nlm.nih.gov/pubmed/35976503 http://dx.doi.org/10.1186/s40658-022-00484-w |
_version_ | 1784769686648389632 |
---|---|
author | Desy, Alessandro Bouvet, Guillaume F. Lafrenière, Nancy Zamanian, Atefeh Després, Philippe Beauregard, Jean-Mathieu |
author_facet | Desy, Alessandro Bouvet, Guillaume F. Lafrenière, Nancy Zamanian, Atefeh Després, Philippe Beauregard, Jean-Mathieu |
author_sort | Desy, Alessandro |
collection | PubMed |
description | BACKGROUND: Dead-time correction is required for accurate quantitative SPECT-based dosimetry in the context of personalised (177)Lu radiopharmaceutical therapy. We aimed to evaluate the impact of applying dead-time correction on the reconstructed SPECT image versus on the acquisition projections before reconstruction. METHODS: Data from 16 SPECT/CT acquisitions of a decaying (177)Lu-filled phantom (up to 20.75 GBq) and dual-timepoint SPECT/CT in 14 patients treated with personalised (177)Lu peptide receptor radionuclide therapy were analysed. Dead time was determined based on the acquisition wide-spectrum count rate for each projection and averaged for the entire acquisition. Three dead-time correction methods (DTCMs) were used: the per-projection correction, where each projection was individually corrected before reconstruction (DTCM1, the standard of reference), and two per-volume methods using the average dead-time correction factor of the acquisition applied to all projections before reconstruction (DTCM2) or to the SPECT image after reconstruction (DTCM3). Relative differences in quantification were assessed for various volumes of interest (VOIs) on the phantom and patient SPECT images. In patients, the resulting dosimetry estimates for tissues of interest were also compared between DTCMs. RESULTS: Both per-volume DTCMs (DTCM2 and DTCM3) were found to be equivalent, with VOI count differences not exceeding 0.8%. When comparing the per-volume post-reconstruction DTCM3 versus the per-projection pre-reconstruction DTCM1, differences in VOI counts and absorbed dose estimates did not exceed 2%, with very few exceptions. The largest absorbed dose deviation was observed for a kidney at 3.5%. CONCLUSION: While per-projection dead-time correction appears ideal for QSPECT, post-reconstruction correction is an acceptable alternative that is more practical to implement in the clinics, and that results in minimal deviations in quantitative accuracy and dosimetry estimates, as compared to the per-projection correction. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40658-022-00484-w. |
format | Online Article Text |
id | pubmed-9385894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-93858942022-08-19 Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy Desy, Alessandro Bouvet, Guillaume F. Lafrenière, Nancy Zamanian, Atefeh Després, Philippe Beauregard, Jean-Mathieu EJNMMI Phys Short Communication BACKGROUND: Dead-time correction is required for accurate quantitative SPECT-based dosimetry in the context of personalised (177)Lu radiopharmaceutical therapy. We aimed to evaluate the impact of applying dead-time correction on the reconstructed SPECT image versus on the acquisition projections before reconstruction. METHODS: Data from 16 SPECT/CT acquisitions of a decaying (177)Lu-filled phantom (up to 20.75 GBq) and dual-timepoint SPECT/CT in 14 patients treated with personalised (177)Lu peptide receptor radionuclide therapy were analysed. Dead time was determined based on the acquisition wide-spectrum count rate for each projection and averaged for the entire acquisition. Three dead-time correction methods (DTCMs) were used: the per-projection correction, where each projection was individually corrected before reconstruction (DTCM1, the standard of reference), and two per-volume methods using the average dead-time correction factor of the acquisition applied to all projections before reconstruction (DTCM2) or to the SPECT image after reconstruction (DTCM3). Relative differences in quantification were assessed for various volumes of interest (VOIs) on the phantom and patient SPECT images. In patients, the resulting dosimetry estimates for tissues of interest were also compared between DTCMs. RESULTS: Both per-volume DTCMs (DTCM2 and DTCM3) were found to be equivalent, with VOI count differences not exceeding 0.8%. When comparing the per-volume post-reconstruction DTCM3 versus the per-projection pre-reconstruction DTCM1, differences in VOI counts and absorbed dose estimates did not exceed 2%, with very few exceptions. The largest absorbed dose deviation was observed for a kidney at 3.5%. CONCLUSION: While per-projection dead-time correction appears ideal for QSPECT, post-reconstruction correction is an acceptable alternative that is more practical to implement in the clinics, and that results in minimal deviations in quantitative accuracy and dosimetry estimates, as compared to the per-projection correction. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40658-022-00484-w. Springer International Publishing 2022-08-17 /pmc/articles/PMC9385894/ /pubmed/35976503 http://dx.doi.org/10.1186/s40658-022-00484-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Short Communication Desy, Alessandro Bouvet, Guillaume F. Lafrenière, Nancy Zamanian, Atefeh Després, Philippe Beauregard, Jean-Mathieu Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy |
title | Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy |
title_full | Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy |
title_fullStr | Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy |
title_full_unstemmed | Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy |
title_short | Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy |
title_sort | impact of the dead-time correction method on quantitative (177)lu-spect (qspect) and dosimetry during radiopharmaceutical therapy |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385894/ https://www.ncbi.nlm.nih.gov/pubmed/35976503 http://dx.doi.org/10.1186/s40658-022-00484-w |
work_keys_str_mv | AT desyalessandro impactofthedeadtimecorrectionmethodonquantitative177luspectqspectanddosimetryduringradiopharmaceuticaltherapy AT bouvetguillaumef impactofthedeadtimecorrectionmethodonquantitative177luspectqspectanddosimetryduringradiopharmaceuticaltherapy AT lafrenierenancy impactofthedeadtimecorrectionmethodonquantitative177luspectqspectanddosimetryduringradiopharmaceuticaltherapy AT zamanianatefeh impactofthedeadtimecorrectionmethodonquantitative177luspectqspectanddosimetryduringradiopharmaceuticaltherapy AT despresphilippe impactofthedeadtimecorrectionmethodonquantitative177luspectqspectanddosimetryduringradiopharmaceuticaltherapy AT beauregardjeanmathieu impactofthedeadtimecorrectionmethodonquantitative177luspectqspectanddosimetryduringradiopharmaceuticaltherapy |